Inhibition of RANK Ligand to treat bone metastases;Inhibition of RANK ligand to treat bone metastases

Bulletin du Cancer

Volumn 100, Issue 11, 2013, Pages 1207-1213

  Body, Jean Jacques ^a  

^a BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Bisphosphonates; Bone metastases; Breast cancer; Denosumab; Prostate cancer

Indexed keywords

CALCIUM; DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; VITAMIN D; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; MONOCLONAL ANTIBODY;

BONE METASTASIS; BREAST CANCER; COST EFFECTIVENESS ANALYSIS; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; MULTIPLE MYELOMA; OSTEOLYSIS; PROSTATE CANCER; REVIEW; BONE METASTASES; BONE TUMOR; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; FEMALE; MALE; METASTASIS; PATHOLOGY; PROSTATE TUMOR; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COMPLICATION; SECONDARY;

BISPHOSPHONATES; BONE METASTASES; BREAST CANCER; DENOSUMAB; PROSTATE CANCER;

ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; HYPOCALCEMIA; IMIDAZOLES; MALE; MULTIPLE MYELOMA; PROSTATIC NEOPLASMS; RANK LIGAND;

EID: 84888996128     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2013.1835     Document Type: Article

References (33)

1. Body JJ, Bartl R, Burckhardt P, et al. Current use of bisphosphonates in oncology. J Clin Oncol 1998 ; 16 : 3890-9
2. Coleman R, Rubens R. The clinical course of bone metastases from breast cancer. Br J Cancer 1987 ; 55 : 61-6
3. Body JJ. Breast Cancer: Bisphosphonate Therapy for Metastatic Bone Disease. Clin Cancer Res 2006 ; 12 : 6258s-63s
4. Vassiliou V, Kalogeropoulou C, Giannopoulou E, Leotsinidis M, Tsota I, Kardamakis D. A novel study investigating the therapeutic outcome of patients with lytic, mixed and sclerotic bone metastases treated with combined radiotherapy and ibandronate. Clin Exp Metastasis 2007 ; 24 : 169-78
5. Plunkett TA, Smith P, Rubens RD. Risk of complications from bone metastases in breast cancer: implications for management. Eur J Cancer 2000 ; 36 : 476-82
6. Yong M, Jensen AO, Jacobsen JB, Norgaard M, Fryezk JP, Sorensen HT. Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007). Breast Cancer Res Treat 2011 ; 129 : 495-503
7. Morrissey C, Roudier MP, Dowell A, et al. Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: results from the University ofWashington Rapid Autopsy Series. J Bone Miner Res 2013 ; 28 : 333-40
8. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004 ; 96 : 879-82
9. Decroisette C, Monnet I, Berard H, et al. Groupe Français de Pneumo-Cancérologie 0601 Team. Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601). J Thorac Oncol 2011 ; 6 : 576-82
10. Beuselinck B, Oudard S, Rixe O, et al. Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol 2011 ; 22 : 794-800
11. Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 2011 ; 48 : 677-92
12. Body JJ. Bisphosphonates in oncology : Focus on clinical experience with pamidronate. Am J Cancer 2005 ; 4 : 293-305
13. Body JJ. Bisphosphonates for malignancy-related bone disease: current status, future developments. Supp Care Cancer 2006 ; 14 : 408-18.
14. Body JJ, Diel IJ, Lichinitzer M, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: Results from two randomised, placebo-controlled phase 3 studies. Br J Cancer 2004 ; 90 : 1133-7.
15. Van Poznak CH, Temin S, Yee GC, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011 ; 29 : 1221-7
16. Body JJ. Denosumab for the management of bone disease in patients with solid tumors. Expert Rev Anticancer Ther 2012 ; 12 : 307-22
17. Lipton A, Steger GG, Figueroa J, et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res 2008 ; 14 : 6690-6
18. Fizazi K, Lipton A, Mariette X, et al. Randomized phase 2 trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009 ; 27 : 1564-71.
19. Body JJ, Lipton A, Gralow J, et al. Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. J Bone Miner Res 2010 ; 25 : 440-6.
20. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic Acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010 ; 28 : 5132-9
21. Cleeland CS, Body JJ, Stopeck A, et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. Cancer 2013 ; 119 : 832-8
22. Martin M, Bell R, Bourgeois H, et al. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase 3 trial of denosumab versus zoledronic acid. Clin Cancer Res 2012 ; 18 : 4841-9.
23. Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE, Delmas PD. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 2000 ; 82 : 858-64
24. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011 ; 377 : 813-22
25. Henry DH, Costa L, Goldwasser F, et al. Randomized, doubleblind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011 ; 29 : 1125-32.
26. Scagliotti GV, Hirsh V, Siena S, et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid. Subgroup analysis from a randomized phase 3 study. J Thorac Oncol 2012 ; 7 : 1823-9
27. Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012 ; 48 : 3082-92
28. Lothgren M, Bracco A, Lucius B, et al. Cost-effectiveness of denosumab vs. zoledronic acid (ZA) for the prevention of skeletal related events (SRE) in patients with bone metastases from solid tumors in the Netherlands. Value Health 2011 ; 14 : A455
29. Body JJ, Chevalier P, Gunther O, Hechmati G, Lamotte M. The economic burden associated with skeletal-related events in patients with bone metastases secondary to solid tumors in Belgium. J Med Econ 2013 ; 16 : 539-46
30. Body JJ. Individualization of bisphosphonate therapy. In : Piccart M, Wood WC, Hung MC, Solin LJ, Cardoso F, eds. Breast cancer management and molecular medicine: Towards tailored approaches. Berlin, Heidelberg, New York : Springer, 2006, p. 545-64.
31. Khosla S, Burr D, Cauley J, et al. American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007 ; 22 : 1479-91
32. Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase 3 trials in cancer patients with bone metastases. Ann Oncol 2011 ; 23 : 1341-7
33. Vandone AM, Donadio M, Mozzati M, et al. Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience. Ann Oncol 2012 ; 23 : 193-200.